IOVA supply chain intelligence for Iovance Biotherapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Iovance Biotherapeutics, Inc. (IOVA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| WUXI-ADVANCED-THERAPIES-INC | WUXI-ADVANCED-THERAPIES-INC | 92% | Since November 2016, we entered into various manufacturing services agreements with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd, or collectively, WuXi, pursuant to whic… |
| WUXI-APPTEC-CO-LTD | WUXI-APPTEC-CO-LTD | 92% | Since November 2016, we entered into various manufacturing services agreements with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd, or collectively, WuXi, pursuant to whic… |
| NOVARTIS-PHARMA-AG | NOVARTIS-PHARMA-AG | 90% | The Company paid an upfront payment to Novartis and may pay future milestones related to initiation of patient dosing in various phases of clinical development for IOV-3001 and approval of the produc… |
| CLLS | Cellectis S.A. | 85% | The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been genetically edited, including a PD-1 inactivated product that the Company refers to a… |
| CLLS | Cellectis S.A. | 85% | Reciprocal relationship from CLLS graph: Reciprocal relationship from IOVA graph: The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been gen… |
| NIH | NIH | 80% | The Company entered into a patent license agreement with the NIH, an agency of the U.S. Public Health Service within the Department of Health and Human Services, in 2011. |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU g… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLINIGEN-SP-LIMITED | CLINIGEN-SP-LIMITED | 85% | NOTE 4. PROLEUKIN ® ACQUISITION On January 23, 2023, the Company and its newly formed, wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the … |
| IOVANCE-BIOTHERAPEUTICS-UK-LTD | IOVANCE-BIOTHERAPEUTICS-UK-LTD | 85% | NOTE 4. PROLEUKIN ® ACQUISITION On January 23, 2023, the Company and its newly formed wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the “… |
| MINARIS-ADVANCED-THERAPIES-INC | MINARIS-ADVANCED-THERAPIES-INC | 85% | nter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the produ… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w… |
| TCRX | TScan Therapeutics, Inc. | 72% | Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | , compared to the same period in 2025. The decrease in our net loss is primarily due to the increase in sales of Amtagvi ® and Proleukin ® products. We anticipate that we will continue to incur net l… |
| CLINIGEN-HOLDINGS-LIMITED-CLINIGEN-HEALTHCARE-LI | CLINIGEN-HOLDINGS-LIMITED-CLINIGEN-HEALTHCARE-LI | 62% | n and manufacturing process, as well as other commercial, clinical, manufacturing, and research settings, which provides additional revenue. In May 2023, we acquired the worldwide rights to Proleukin… |
| CORNER-POST-INC | CORNER-POST-INC | 62% | or lowering the cost of healthcare, including drugs and biologics. Any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and … |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | s. Other than our Gen 2 manufacturing process rights, our TIL composition of matter rights, our method of use rights in certain indications, and our licensed rights, we currently do not own any exclu… |
| PHILADELPHIA-INDUSTRIAL-DEVELOPMENT-CORPORATION | PHILADELPHIA-INDUSTRIAL-DEVELOPMENT-CORPORATION | 62% | candidates and commercialization of our products, and if we are unable to obtain such financing, we may be unable to complete the development of our product candidates and commercialization of our pr… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IOVA-DEBT-10333 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2018-12-31. |
| IOVA-DEBT | Debt stack $47.8M | 90% | Market cache reports total debt of $47.8M. |
| IOVA-DEBT-10332 | Warrants outstanding: 15754000 | 90% | xbrl warrant detail from xbrl 2018-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IOVA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 289 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| GNLX | Genelux Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| TMO | Thermo Fisher Scientific Inc. | 100.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 100.00 | 2 | |
| LYEL | Lyell Immunopharma, Inc. | 100.00 | 2 | |
| NTLA | Intellia Therapeutics, Inc. | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 2 | |
| LEGN | Legend Biotech Corporation | 50.00 | 2 | |
| LLY | Eli Lilly and Company | 50.00 | 2 | |
| ONCY | Oncolytics Biotech Inc. | 50.00 | 2 | |
| PRME | Prime Medicine, Inc. | 50.00 | 2 | |
| IPSC | Century Therapeutics, Inc. | 50.00 | 2 | |
| CMOS | CMOS | 50.00 | 2 | |
| TOVX | Theriva Biologics, Inc. | 50.00 | 2 |